Menu Search
Equities

Racura Oncology Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
FN3:FRA

Racura Oncology Ltd

Actions
  • Price (EUR)1.37
  • Today's Change0.03 / 2.24%
  • Shares traded581.00
  • 1 Year change+91.61%
  • Beta0.6007
Data delayed at least 15 minutes, as of Feb 10 2026 08:55 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Racura Oncology Ltd, formerly Race Oncology Limited, is an Australia-based Phase III clinical biopharmaceutical company with a focus on cancer care. The Company's lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via G4-DNA and RNA binding, leading to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterized safety profile. The Company is advancing a formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with Phase III clinical programs in acute myeloid leukemia (AML), a Phase I a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase I a/b program in combination with the anthracycline doxorubicin, where the Company is focused on delivering both cardioprotection and enhanced anticancer activity for solid tumor patients.

  • Revenue in AUD (TTM)788.42k
  • Net income in AUD-4.79m
  • Incorporated2011
  • Employees--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.